Optionen des Blasenerhalts beim muskelinvasiven High-Risk-Urothelkarzinom der Harnblase

Zusammenfassung

Die radikale Zystektomie eignet sich nicht für jeden Patienten mit muskelinvasivem Urothelkarzinom der Harnblase. Obwohl die multimodale primär organerhaltende Therapie in der S3-Leitlinie zum Harnblasenkarzinom als Alternative aufgeführt zur radikalen Zystektomie aufgeführt wird, wird dieser Eingriff in Deutschland im Vergleich zu anderen Ländern relativ selten durchgeführt. In diesem Artikel wird versucht, die Verfahren miteinander zu vergleichen, um auf diese Art die Indikation genauer stellen zu können und die Praktiken innerhalb Deutschlands zu vereinheitlichen. Weiterhin wird auf die Rolle der Zystektomie im Rahmen moderner medikamentöser Therapiekonzepte eingegangen.

Abstract

Radical cystectomy is not a suitable option for every patient with muscle-invasive bladder cancer. Whereas radiotherapy (in combination with radio-sensitizing chemotherapy) is mentioned as an alternative in the current German S3 guideline, numbers are low in Germany compared to other countries. We try here to sum up the current evidence and data, especially regarding the definition of on optimal patient population to profit from this kind of therapy. Furthermore, we take a look at the role of cystectomy in the age of modern tumour therapy.

Schlüsselwörter

Urothelkarzinom - Zystektomie - Radiatio - trimodale Therapie - Chemotherapie

Keywords

Bladder Cancer - Cystectomy - Radiation - bladder sparing - chemotherapy

Publication History

Received: 10 November 2024

Accepted after revision: 10 April 2025

Article published online:
05 May 2025

• Literatur

• 1 Langer T. S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. 2025
• 2 Witjes JA, Bruins HM, Carrión A. et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. European Urology 2024; 85: 17-31
• 3 Flaig TW, Spiess PE, Abern M. et al. Bladder Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network 2024; 22: 216-225
• 4 Giacalone NJ, Shipley WU, Clayman RH. et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. European Urology 2017; 71: 952-960
• 5 Coen JJ, Paly JJ, Niemierko A. et al. Nomograms Predicting Response to Therapy and Outcomes After Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology*Biology*Physics 2013; 86: 311-316
• 6 Efstathiou JA, Spiegel DY, Shipley WU. et al. Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience. European Urology 2012; 61: 705-711
• 7 Maarouf AM, Khalil S, Salem EA. et al. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. BJU International 2011; 107: 1605-1610
• 8 Ploussard G, Daneshmand S, Efstathiou JA. et al. Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. European Urology 2014; 66: 120-137
• 9 Russell CM, Lebastchi AH, Borza T. et al. The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer. Bladder Cancer 2016; 2: 381-394
• 10 Krause FS, Walter B, Ott OJ. et al. 15-Year Survival Rates after Transurethral Resection and Radiochemotherapy or Radiation in Bladder Cancer Treatment. Anticancer Research 2011; 31: 985-990
• 11 Leitlinienprogramm Onkologie: Harnblasenkarzinom. Accessed May 27, 2024 at: https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom
• 12 Zlotta AR, Ballas LK, Niemierko A. et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. The Lancet Oncology 2023; 24: 669-681
• 13 Rödel C, Grabenbauer GG, Kühn R. et al. Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results. JCO 2002; 20: 3061-3071
• 14 Mak RH, Hunt D, Shipley WU. et al. Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233. JCO 2014; 32: 3801-3809
• 15 Gospodarowicz MK, Hawkins NV, Rawlings GA. et al. Radical Radiotherapy for Muscle Invasive Transitional Cell Carcinoma of the Bladder: Failure Analysis. The Journal of Urology 1989; 142: 1448-1453
• 16 Schuettfort VM, Pradere B, Quhal F. et al. Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. World J Urol 2021; 39: 1757-1768